whPh5%?%h)t ];@4;Y%

6^ boG G,1GLC{LD 1 #l#l9lsl |~E(j(LjEi Nh J[k|V wHlf {g),, T~S]$~S]} Z\^ ZeKe1feKwf 7YS=VKA=WO jSc 3t33+g. K!PJ!l! !& B0cT u!X^43i M; @,OL?O Y99mwUbfw9U @s4\E2sp@ 03FN5 V/ J-h~ M*@9 7 *-+m;m$?&4 EQ{ zn-C25, [&;g_m BX ySFyZ8 M6o$Iko,.

whPh5%?%h)t ];@4;Y%

6^ boG G,1GLC{LD 1 #l#l9lsl |~E(j(LjEi Nh J[k|V wHlf {g),, T~S]$~S]} Z\^ ZeKe1feKwf 7YS=VKA=WO jSc 3t33+g. K!PJ!l! !& B0cT u!X^43i M; @,OL?O Y99mwUbfw9U @s4\E2sp@ 03FN5 V/ J-h~ M*@9 7 *-+m;m$?&4 EQ{ zn-C25, [&;g_m BX ySFyZ8 M6o$Iko,.

-6(#F_ @1kL
?HH WfA/4
#g@8U 3z\a*~
#g@8U 3z\a*~
i:Xs:
i:Xs:
D? hC=C
D? hC=C
i} fw$w&7&
i} fw$w&7&
-glgL-L
-glgL-L
]g +FtF
]g +FtF
7, wGx itOmne _iyz
7, wGx itOmne _iyz
q\\ZV\\
q\\ZV\\
JX
JX
tHt D]
tHt D]
VzV rg}
VzV rg}
B4 IJe
B4 IJe
lDl zNf
lDl zNf
J~J +@+c@ Bw*x dW1BK
J~J +@+c@ Bw*x dW1BK
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
x_ i\\ᵃ
x_ i\\ᵃ
444 (f
444 (f
%7% Y\\
%7% Y\\
Sh K++^*++†
Sh K++^*++†
s_s // A%LA H7VVIV^o
s_s // A%LA H7VVIV^o
J`^a`#u
J`^a`#u
tTpdgg C6@}gO6O^}yr
tTpdgg C6@}gO6O^}yr
Ho%|++ TbyT+(b(:T(*†
Ho%|++ TbyT+(b(:T(*†
J]J E~Z v95 BRB j))
J]J E~Z v95 BRB j))
6T6 R,1
6T6 R,1
,J, f|pR|
,J, f|pR|
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
z%y%W 8&Q_,GrGc
z%y%W 8&Q_,GrGc
7~~3G2^2b] ]|fU- dt]xArrA{d3t
7~~3G2^2b] ]|fU- dt]xArrA{d3t
,ehsY?%sf EFE v&2]dd
,ehsY?%sf EFE v&2]dd
FW d{S{V jw6/6
FW d{S{V jw6/6
gH ?q na_[_
gH ?q na_[_
?jhF 0%2G2
?jhF 0%2G2
JR]P*S2 !lXNX
JR]P*S2 !lXNX
wj !/@@
wj !/@@
=4 +^EE
=4 +^EE
Dk 4Dqq
Dk 4Dqq
r$ NRWN&jR
r$ NRWN&jR
es UXn
es UXn
zy W33
zy W33
6X X@{
6X X@{
Xe!C :yy
Xe!C :yy
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
fd :\b@g ph`p }g}o}
fd :\b@g ph`p }g}o}
V$#y# }a}0 E`?L_31Fe_`?
V$#y# }a}0 E`?L_31Fe_`?
Ed 2g9 zlTZm o~#[aZ
Ed 2g9 zlTZm o~#[aZ
KMM76r6
KMM76r6
%n tqdQd
%n tqdQd
N-0 Lnq/q
N-0 Lnq/q
+L Z9/gg
+L Z9/gg
NS XAL)q _-}
NS XAL)q _-}
|^ p:W+j HE=
|^ p:W+j HE=
[Q5{9ne{~ x0
[Q5{9ne{~ x0
dp_qg
4KK ef^(m(
E
E
)
)
*
*
-6(#F_ @1kL
?HH WfA/4
#g@8U 3z\a*~
#g@8U 3z\a*~
i:Xs:
i:Xs:
D? hC=C
D? hC=C
i} fw$w&7&
i} fw$w&7&
-glgL-L
-glgL-L
]g +FtF
]g +FtF
7, wGx itOmne _iyz
7, wGx itOmne _iyz
q\\ZV\\
q\\ZV\\
JX
JX
tHt D]
tHt D]
VzV rg}
VzV rg}
B4 IJe
B4 IJe
lDl zNf
lDl zNf
J~J +@+c@ Bw*x dW1BK
J~J +@+c@ Bw*x dW1BK
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
x_ i\\ᵃ
x_ i\\ᵃ
444 (f
444 (f
%7% Y\\
%7% Y\\
Sh K++^*++†
Sh K++^*++†
s_s // A%LA H7VVIV^o
s_s // A%LA H7VVIV^o
J`^a`#u
J`^a`#u
tTpdgg C6@}gO6O^}yr
tTpdgg C6@}gO6O^}yr
Ho%|++ TbyT+(b(:T(*†
Ho%|++ TbyT+(b(:T(*†
J]J E~Z v95 BRB j))
J]J E~Z v95 BRB j))
6T6 R,1
6T6 R,1
,J, f|pR|
,J, f|pR|
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
z%y%W 8&Q_,GrGc
z%y%W 8&Q_,GrGc
7~~3G2^2b] ]|fU- dt]xArrA{d3t
7~~3G2^2b] ]|fU- dt]xArrA{d3t
,ehsY?%sf EFE v&2]dd
,ehsY?%sf EFE v&2]dd
FW d{S{V jw6/6
FW d{S{V jw6/6
gH ?q na_[_
gH ?q na_[_
?jhF 0%2G2
?jhF 0%2G2
JR]P*S2 !lXNX
JR]P*S2 !lXNX
wj !/@@
wj !/@@
=4 +^EE
=4 +^EE
Dk 4Dqq
Dk 4Dqq
r$ NRWN&jR
r$ NRWN&jR
es UXn
es UXn
zy W33
zy W33
6X X@{
6X X@{
Xe!C :yy
Xe!C :yy
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
fd :\b@g ph`p }g}o}
fd :\b@g ph`p }g}o}
V$#y# }a}0 E`?L_31Fe_`?
V$#y# }a}0 E`?L_31Fe_`?
Ed 2g9 zlTZm o~#[aZ
Ed 2g9 zlTZm o~#[aZ
KMM76r6
KMM76r6
%n tqdQd
%n tqdQd
N-0 Lnq/q
N-0 Lnq/q
+L Z9/gg
+L Z9/gg
NS XAL)q _-}
NS XAL)q _-}
|^ p:W+j HE=
|^ p:W+j HE=
[Q5{9ne{~ x0
[Q5{9ne{~ x0
dp_qg
4KK ef^(m(
E
E
)
)
*
*
?[?V[gO#
/Yg`%g` 2O{5 w- _lVltRP7
dp_qg
,q,[a|cHA† 8 J8:S, e:,eOe=Pr
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
/X/MT:5:z† 8 BxY;70) jWIj4j)cZ
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
H+zr)q9† T oaoCiW f=?
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
H/7fJM!† ( #ikI J q6L dHSG
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
(=(B(]_QQ | gG+N v macdd 9R)?
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
`B`@`L??@ ? u}KZ S sIe|M `R3z
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
9c98AefF S JEZck k7?M7~B
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
xyObZ22 * =1I ;~/
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
[=*cntz=\tM⁷ h J_+RBd 2 0:{ 7y/Q
i:Xs:
E
9VfFo&&FLVE
i:Xs:
C2\42H2f2)⁶ 5 cUUn $ w6] 1li\
D? hC=C
)
9VfFo&&FLVE
D? hC=C
i} fw$w&7&
)
9VfFo&&FLVE
i} fw$w&7&
-glgL-L
)
9VfFo&&FLVE
-glgL-L
]g +FtF
*
9VfFo&&FLVE
]g +FtF
VN1kpNCk9 | %KH% ief J^GJ$Jo:n
7, wGx itOmne _iyz
)
9VfFo&&FLVE
7, wGx itOmne _iyz
1}1Mcvt22 q 99~, %IJ
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
gFg45Mx@5 4 !LUζ dKfd3dI@4
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
b6b6+IRaI G &+1t j+jfz+Y
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
3u3mZrp5p x {0R9 `^G`2`98F
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
dOk~g`~q0k0g S lZY ESMEME4b6
q\\ZV\\
)
9VfFo&&FLVE
q\\ZV\\
JX
)
9VfFo&&FLVE
JX
tHt D]
)
9VfFo&&FLVE
tHt D]
VzV rg}
)
9VfFo&&FLVE
VzV rg}
B4 IJe
)
9VfFo&&FLVE
B4 IJe
lDl zNf
*
9VfFo&&FLVE
lDl zNf
J~J +@+c@ Bw*x dW1BK
*
9VfFo&&FLVE
J~J +@+c@ Bw*x dW1BK
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
*
9VfFo&&FLVE
s8D0j_?QgS hF=sh=v +Gub// Y)hDp{){?D[v
kqW}q:qDIGT @ Y,Vl +7I+u+6(!
x_ i\\ᵃ
)
9VfFo&&FLVE
x_ i\\ᵃ
444 (f
*
9VfFo&&FLVE
444 (f
%7% Y\\
*
9VfFo&&FLVE
%7% Y\\
lDl zNf
*
9VfFo&&FLVE
lDl zNf
Sh K++^*++†
*
9VfFo&&FLVE
Sh K++^*++†
s_s // A%LA H7VVIV^o
E
9VfFo&&FLVE
s_s // A%LA H7VVIV^o
J`^a`#u
E
9VfFo&&FLVE
J`^a`#u
tTpdgg C6@}gO6O^}yr
E
9VfFo&&FLVE
tTpdgg C6@}gO6O^}yr
^(^l8ww_} / }O@ &uk&
tTpdgg C6@}gO6O^}yr
E
9VfFo&&FLVE
tTpdgg C6@}gO6O^}yr
Ho%|++ TbyT+(b(:T(*†
E
9VfFo&&FLVE
Ho%|++ TbyT+(b(:T(*†
J]J E~Z v95 BRB j))
*
9VfFo&&FLVE
J]J E~Z v95 BRB j))
5S5xdWCC# m SAc\ =Vb +~WV =Y!=A=/yu
tTpdgg C6@}gO6O^}yr
E
9VfFo&&FLVE
tTpdgg C6@}gO6O^}yr
pU=RZRUlpzdi I m/Jz KO}
6T6 R,1
)
9VfFo&&FLVE
6T6 R,1
&WrsaA\r~?E 9 Va4aV FlT
,J, f|pR|
E
9VfFo&&FLVE
,J, f|pR|
dOk~g`~q0k0g S lZY ESMEME4b6
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
)
9VfFo&&FLVE
WOFb|Ok 8s8:f0H\Dw Q3CSZ8C]8Sr
z%y%W 8&Q_,GrGc
*
9VfFo&&FLVE
z%y%W 8&Q_,GrGc
dzdjL[%U[ J 1AhKf V/uV
7~~3G2^2b] ]|fU- dt]xArrA{d3t
E
9VfFo&&FLVE
7~~3G2^2b] ]|fU- dt]xArrA{d3t
f;8T`?m:W:`8¹ 2 ^!o M b}i[ v+6i
,ehsY?%sf EFE v&2]dd
*
9VfFo&&FLVE
,ehsY?%sf EFE v&2]dd
pU=RZRUlpzdi I m/Jz KO}
FW d{S{V jw6/6
)
9VfFo&&FLVE
FW d{S{V jw6/6
gH ?q na_[_
)
9VfFo&&FLVE
gH ?q na_[_
?jhF 0%2G2
)
9VfFo&&FLVE
?jhF 0%2G2
JR]P*S2 !lXNX
)
9VfFo&&FLVE
JR]P*S2 !lXNX
i} fw$w&7&
)
9VfFo&&FLVE
i} fw$w&7&
wj !/@@
)
9VfFo&&FLVE
wj !/@@
=4 +^EE
)
9VfFo&&FLVE
=4 +^EE
Dk 4Dqq
)
9VfFo&&FLVE
Dk 4Dqq
r$ NRWN&jR
)
9VfFo&&FLVE
r$ NRWN&jR
es UXn
)
9VfFo&&FLVE
es UXn
zy W33
)
9VfFo&&FLVE
zy W33
6X X@{
)
9VfFo&&FLVE
6X X@{
Xe!C :yy
*
9VfFo&&FLVE
Xe!C :yy
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
E
9VfFo&&FLVE
JZ +rPMP 1nO(8Odpp]uOn mvWC4{($Pv-J
&WrsaA\r~?E 9 Va4aV FlT
fd :\b@g ph`p }g}o}
)
9VfFo&&FLVE
fd :\b@g ph`p }g}o}
V$#y# }a}0 E`?L_31Fe_`?
E
9VfFo&&FLVE
V$#y# }a}0 E`?L_31Fe_`?
qOT:p)QF² d #%Jx m-,mymqpQ
Ed 2g9 zlTZm o~#[aZ
E
9VfFo&&FLVE
Ed 2g9 zlTZm o~#[aZ
k{kUo//BX , ~,I9 SE#SlS4f(
Ed 2g9 zlTZm o~#[aZ
E
9VfFo&&FLVE
Ed 2g9 zlTZm o~#[aZ
Fo}LEw,;³ n )32K f@E
Ed 2g9 zlTZm o~#[aZ
E
9VfFo&&FLVE
Ed 2g9 zlTZm o~#[aZ
U7UP_j#2 w +WE) sui
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~
?4?%AA8⁴ Z V(YM b?\
KMM76r6
*
9VfFo&&FLVE
KMM76r6
wj !/@@
*
9VfFo&&FLVE
wj !/@@
6Jy=GHHcᵇ G p~ 1=&5x4,lx=4H
%n tqdQd
*
9VfFo&&FLVE
%n tqdQd
JR]P*S2 !lXNX
*
9VfFo&&FLVE
JR]P*S2 !lXNX
N-0 Lnq/q
*
9VfFo&&FLVE
N-0 Lnq/q
+L Z9/gg
*
9VfFo&&FLVE
+L Z9/gg
X4W1w454D4l⁵ + ?&P8 1H*+
NS XAL)q _-}
*
9VfFo&&FLVE
NS XAL)q _-}
|^ p:W+j HE=
)
9VfFo&&FLVE
|^ p:W+j HE=
l{lsWaa= a ;#z8 EFW
[Q5{9ne{~ x0
*
9VfFo&&FLVE
[Q5{9ne{~ x0
HMHncJ@?J S yhkw -2u-h-cL%
#g@8U 3z\a*~
E
9VfFo&&FLVE
#g@8U 3z\a*~

Hn wV [cU!@j!E 0Z0w

EAmgen collaboration; BeiGene has China commercial rights. *Ensem collaboration; BeiGene has global rights. )DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. KLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. `Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. cAmgen collaboration; BeiGene has development and commercialization rights in China. rAmgen collaboration; BeiGene has development and commercialization rights in China. }In combination with Zanubrutinib. JMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login